OSTX · OS Therapies Inc · Executive Compensation
$1.26
-0.01 (-0.79%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$58.58M
Shares
46.13M
Volume · Oct 20
319.82K
Avg daily vol (3M)
581.18K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Paul A. Romness | MPH President and Chief Executive Officer | $1,942,168 |
| Robert G. Petit | Chief Medical and Scientific Officer | $1,030,000 |
| Christopher P. Acevedo | Chief Financial Officer | $280,000 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul A. Romness | MPH President and Chief Executive Officer | $3,434,316 |
| Robert G. Petit | Chief Medical and Scientific Officer | $665,046 |
| Christopher P. Acevedo | Chief Financial Officer | $158,523 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Paul A. Romness | MPH President and Chief Executive Officer | $360,000 |
| Robert G. Petit | Chief Medical and Scientific Officer | $300,000 |
| Christopher P. Acevedo | Chief Financial Officer | $36,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Frank Knuettel II | Chief Financial Officer | Appointed | 2026-10-05 |
| Kerry Clem | Chief Commercial Officer | Appointed | 2026-10-05 |
| Kerry Clem | Chief Commercial Officer | Appointed | 2026-10-05 |
| Francis (Frank) Knuettel II | Chief Financial Officer | Appointed | 2026-10-05 |
| Theodore F. Search | director | Appointed | 2026-09-09 |
| Olivier R. Jarry | director | Appointed | 2026-09-09 |
| Craig Eagle | director | Appointed | 2026-09-09 |
| Avril McKean Dieser | director | Appointed | 2026-09-09 |
| John Ciccio | director | Appointed | 2026-09-09 |
| Paul A. Romness | director | Appointed | 2026-09-09 |
| Dr. Craig Eagle | Board of Directors | Appointed | 2026-07-02 |
| Dr. Craig Eagle | board of directors | Appointed | 2026-07-02 |
| Karim Galzahr | board of directors | Resigned | 2026-07-02 |
| Karim Galzahr | Board of Directors | Appointed | 2025-01-29 |
| Karim Galzahr | board of directors | Appointed | 2025-01-29 |
| Olivier R. Jarry | director | Appointed | 2024-10-28 |
| Colin Goddard, Ph.D. | director | Resigned | 2024-10-28 |
| Avril McKean Dieser | director | Appointed | 2024-10-28 |
| Joacim Borg | director | Resigned | 2024-10-28 |
| Colin Goddard, Ph.D. | Chairman of the Board | Resigned | 2024-10-28 |
Leadership
- Paul A. Romness CEO, Board Member
- Christopher P. Acevedo CFO
- Francis (Frank) Knuettel II CFO
- Frank Knuettel II CFO
- Avril McKean Dieser Board Member
- Craig Eagle Board Member
- Dr. Craig Eagle Board Member
- John Ciccio Board Member
- Karim Galzahr Board Member
- Olivier R. Jarry Board Member
- Theodore F. Search Board Member